Literature DB >> 29181680

The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer.

John M Creasy1, Eran Sadot1, Bas Groot Koerkamp1, Joanne F Chou2, Mithat Gonen2, Nancy E Kemeny3, Leonard B Saltz3, Vinod P Balachandran1, T Peter Kingham1, Ronald P DeMatteo1, Peter J Allen1, William R Jarnagin1, Michael I D'Angelica4,5.   

Abstract

BACKGROUND: The impact of primary tumor location on overall survival (OS), recurrence-free survival (RFS), and long-term outcomes has not been well established in patients undergoing potentially curative resection of colorectal liver metastases (CRLM).
METHODS: A single-institution database was queried for initial resections for CRLM 1992-2004. Primary tumor location determined by chart review (right = cecum to transverse; left = splenic flexure to sigmoid). Rectal cancer (distal 16 cm), multiple primaries, and unknown location were excluded. Kaplan-Meier and Cox regression methods were used. Cure was defined as actual 10-year survival with either no recurrence or resected recurrence with at least 3 years of disease-free follow-up.
RESULTS: A total of 907 patients were included with a median follow-up of 11 years; 578 patients (64%) had left-sided and 329 (36%) right-sided primaries. Median OS for patients with a left-sided primary was 5.2 years (95% confidence interval [CI] 4.6-6.0) versus 3.6 years (95% CI 3.2-4.2) for right-sided (p = 0.004). On multivariable analysis, the hazard ratio for right-sided tumors was 1.22 (95% CI 1.02-1.45, p = 0.028) after adjusting for common clinicopathologic factors. Median RFS was marginally different stratified by primary location (1.3 vs. 1.7 years; p = 0.065). On multivariable analysis, location of primary was not significantly associated with RFS (p = 0.105). Observed cure rates were 22% for left-sided and 20% for right-sided tumors.
CONCLUSIONS: Among patients undergoing resection of CRLM, left-sided primary tumors were associated with improved median OS. However, long-term survival and recurrence-free survival were not significantly different stratified by primary location. Patients with left-sided primary tumors displayed a prolonged clinical course suggestive of more indolent biology.

Entities:  

Mesh:

Year:  2017        PMID: 29181680      PMCID: PMC7480216          DOI: 10.1245/s10434-017-6264-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  28 in total

1.  What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up.

Authors:  Carlo Pulitanò; Federico Castillo; Luca Aldrighetti; Martin Bodingbauer; Rowan W Parks; Gianfranco Ferla; Stephen J Wigmore; O James Garden
Journal:  HPB (Oxford)       Date:  2010-05       Impact factor: 3.647

2.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.

Authors:  N Kemeny; Y Huang; A M Cohen; W Shi; J A Conti; M F Brennan; J R Bertino; A D Turnbull; D Sullivan; J Stockman; L H Blumgart; Y Fong
Journal:  N Engl J Med       Date:  1999-12-30       Impact factor: 91.245

3.  Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.

Authors:  Frank Benedix; Frank Meyer; Rainer Kube; Siegfried Kropf; Doerthe Kuester; Hans Lippert; Albert Roessner; Sabine Krüger
Journal:  Pathol Res Pract       Date:  2012-08-13       Impact factor: 3.250

4.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Authors:  Julian Walter Holch; Ingrid Ricard; Sebastian Stintzing; Dominik Paul Modest; Volker Heinemann
Journal:  Eur J Cancer       Date:  2016-11-29       Impact factor: 9.162

5.  Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases.

Authors:  Peter J Allen; Aviram Nissan; Antonio I Picon; Nancy Kemeny; Paul Dudrick; Leah Ben-Porat; Joseph Espat; Alexander Stojadinovic; Alfred M Cohen; Yuman Fong; Philip B Paty
Journal:  J Am Coll Surg       Date:  2005-07       Impact factor: 6.113

6.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Authors:  Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

7.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

8.  Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.

Authors:  Georgios Karagkounis; Michael S Torbenson; Hubert D Daniel; Nilofer S Azad; Luis A Diaz; Ross C Donehower; Kenzo Hirose; Nita Ahuja; Timothy M Pawlik; Michael A Choti
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

9.  Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity.

Authors:  Luca Viganò; Alessandro Ferrero; Roberto Lo Tesoriere; Lorenzo Capussotti
Journal:  Ann Surg Oncol       Date:  2008-05-08       Impact factor: 5.344

10.  Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.

Authors:  B Nordlinger; M Guiguet; J C Vaillant; P Balladur; K Boudjema; P Bachellier; D Jaeck
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

View more
  22 in total

Review 1.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

2.  Clinical Impact of Operative Order in Laparoscopic Simultaneous Resection for Synchronous Colorectal Liver Metastases.

Authors:  Takuya Tajiri; Hiromitsu Hayashi; Yuji Miyamoto; Katsunori Imai; Yuki Kitano; Takayoshi Kaida; Hiroshi Sawayama; Toru Beppu; Yo-Ichi Yamashita; Hideo Baba
Journal:  Cancer Diagn Progn       Date:  2021-07-03

3.  Does the primary tumour location affect the prognosis of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

Authors:  Haipeng Chen; Sicheng Zhou; Jianjun Bi; Qiang Feng; Zheng Jiang; Jianping Xu; Wei Pei; Jianwei Liang; Zhixiang Zhou; Xishan Wang
Journal:  World J Surg Oncol       Date:  2021-08-26       Impact factor: 2.754

4.  Nomogram Predicting the Survival of Young-Onset Patients with Colorectal Cancer Liver Metastases.

Authors:  Xiaofei Cheng; Yanqing Li; Dong Chen; Xiangming Xu; Fanlong Liu; Feng Zhao
Journal:  Diagnostics (Basel)       Date:  2022-06-04

5.  Association of primary tumor laterality with surgical outcomes for colorectal liver metastases: results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC).

Authors:  Cristian D Valenzuela; Omeed Moaven; Rohin Gawdi; John A Stauffer; Nico R Del Piccolo; Tan To Cheung; Carlos U Corvera; Andrew D Wisneski; Charles Cha; Christopher W Mangieri; Nima P Zarandi; Justin Dourado; Kathleen C Perry; Gregory Russell; Perry Shen
Journal:  HPB (Oxford)       Date:  2022-02-28       Impact factor: 3.842

6.  Long-term Results of Surgery for Colorectal Liver Metastases in Terms of Primary Tumour Location and Clinical Risk Factors.

Authors:  Vladislav Treska; Martin Skala; Kristyna Prochazkova; Aneta Svejdova; Tereza Petrakova; Jakub Sebek; Ivan Riha; Jachym Rosendorf; Robert Polak; Tomas Skalicky; Vaclav Liska
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

7.  Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer.

Authors:  Andrea Di Giorgio; Francesco Santullo; Miriam Attalla El Halabieh; Claudio Lodoli; Carlo Abatini; Maria Alessandra Calegari; Maurizio Martini; Stefano Rotolo; Fabio Pacelli
Journal:  J Gastrointest Surg       Date:  2021-07-09       Impact factor: 3.452

8.  Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?

Authors:  Thomas Boerner; Constantinos Zambirinis; Johan Gagnière; Joanne F Chou; Mithat Gonen; Nancy E Kemeny; Andrea Cercek; Louise C Connell; Thomas P Kingham; Peter J Allen; Vinod P Balachandran; Jeffrey Drebin; William R Jarnagin; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2020-09-14       Impact factor: 3.647

9.  Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin.

Authors:  Mohammad Adileh; Jonathan B Yuval; Henry S Walch; Walid K Chatila; Rona Yaeger; Julio Garcia-Aguilar; Nikolaus Schultz; Philip B Paty; Andrea Cercek; Garrett M Nash
Journal:  Ann Surg Oncol       Date:  2020-08-25       Impact factor: 5.344

10.  Management of indeterminate hepatic nodules and evaluation of factors predicting their malignant potential in patients with colorectal cancer.

Authors:  Mizelle D'Silva; Jai Young Cho; Ho-Seong Han; Taupyk Yerlan; Yoo-Seok Yoon; Hae Won Lee; Jun Suh Lee; Boram Lee; Moonhwan Kim
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.